189 related articles for article (PubMed ID: 23704714)
1. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection.
Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A
Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group.
Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK
J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162
[TBL] [Abstract][Full Text] [Related]
3. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
Lerario AM; Worden FP; Ramm CA; Hesseltine EA; Stadler WM; Else T; Shah MH; Agamah E; Rao K; Hammer GD
Horm Cancer; 2014 Aug; 5(4):232-9. PubMed ID: 24849545
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study.
Terzolo M; Fassnacht M; Perotti P; Libé R; Kastelan D; Lacroix A; Arlt W; Haak HR; Loli P; Decoudier B; Lasolle H; Quinkler M; Haissaguerre M; Chabre O; Caron P; Stigliano A; Giordano R; Zatelli MC; Bancos I; Fragoso MCBV; Canu L; Luconi M; Puglisi S; Basile V; Reimondo G; Kroiss M; Megerle F; Hahner S; Kimpel O; Dusek T; Nölting S; Bourdeau I; Chortis V; Ettaieb MH; Cosentini D; Grisanti S; Baudin E; Berchialla P; Bovis F; Sormani MP; Bruzzi P; Beuschlein F; Bertherat J; Berruti A
Lancet Diabetes Endocrinol; 2023 Oct; 11(10):720-730. PubMed ID: 37619579
[TBL] [Abstract][Full Text] [Related]
5. Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma.
Altieri B; Kimpel O; Megerle F; Detomas M; Chifu I; Fuss CT; Quinkler M; Kroiss M; Fassnacht M
Eur J Endocrinol; 2024 Feb; 190(2):139-150. PubMed ID: 38244214
[TBL] [Abstract][Full Text] [Related]
6. Inflammation-based scores as predictors of treatment response in advanced adrenocortical carcinoma.
Mangone A; Altieri B; Detomas M; Prete A; Abbas H; Asia M; Elhassan YS; Mantovani G; Ronchi CL
Endocr Relat Cancer; 2023 Apr; 30(4):. PubMed ID: 36715606
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomic analysis in adrenocortical carcinoma reveals genetic features associated with mitotane sensitivity and potential therapeutics.
Zhang J; Wu L; Su T; Liu H; Jiang L; Jiang Y; Wu Z; Chen L; Li H; Zheng J; Sun Y; Peng H; Han R; Ning G; Ye L; Wang W
Front Endocrinol (Lausanne); 2024; 15():1365321. PubMed ID: 38779454
[TBL] [Abstract][Full Text] [Related]
8. New Findings on Presentation and Outcome of Patients With Adrenocortical Cancer: Results From a National Cohort Study.
Puglisi S; Calabrese A; Ferraù F; Violi MA; Laganà M; Grisanti S; Ceccato F; Scaroni C; Di Dalmazi G; Stigliano A; Altieri B; Canu L; Loli P; Pivonello R; Arvat E; Morelli V; Perotti P; Basile V; Berchialla P; Urru S; Fiori C; Porpiglia F; Berruti A; Pia A; Reimondo G; Cannavò S; Terzolo M
J Clin Endocrinol Metab; 2023 Sep; 108(10):2517-2525. PubMed ID: 37022947
[TBL] [Abstract][Full Text] [Related]
9. International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects.
Riedmeier M; Antonini SRR; Brandalise S; Costa TEJB; Daiggi CM; de Figueiredo BC; de Krijger RR; De Sá Rodrigues KE; Deal C; Del Rivero J; Engstler G; Fassnacht M; Fernandes Luiz Canali GC; Molina CAF; Gonc EN; Gültekin M; Haak HR; Guran T; Hendriks Allaird EJ; Idkowiak J; Kuhlen M; Malkin D; Meena JP; Pamporaki C; Pinto E; Puglisi S; Ribeiro RC; Thompson LDR; Yalcin B; Van Noesel M; Wiegering V
Eur J Endocrinol; 2024 Mar; 190(4):G15-G24. PubMed ID: 38552173
[TBL] [Abstract][Full Text] [Related]
10. Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?
Wierman ME
Lancet Oncol; 2024 May; 25(5):534-535. PubMed ID: 38608692
[No Abstract] [Full Text] [Related]
11. Immediate versus modified release hydrocortisone in mitotane-treated patients with adrenocortical cancer.
Weigel M; Hahner S; Sherlock M; Agha A; Behan LA; Stewart PM; Arlt W; Beier D; Frey K; Zopf K; Quinkler M
Clin Endocrinol (Oxf); 2017 Apr; 86(4):499-505. PubMed ID: 28063163
[TBL] [Abstract][Full Text] [Related]
12. Impact of EDP-M on survival of patients with metastatic adrenocortical carcinoma: A population-based study.
Debets P; Dreijerink KMA; Engelsman A; Dahele M; Haak HR; Steenaard RV; Kapiteijn E; Corssmit E; Menke-van der Houven van Oordt CW
Eur J Cancer; 2024 Jan; 196():113424. PubMed ID: 37977106
[TBL] [Abstract][Full Text] [Related]
13. Urine Steroid Metabolomics as a Novel Tool for Detection of Recurrent Adrenocortical Carcinoma.
Chortis V; Bancos I; Nijman T; Gilligan LC; Taylor AE; Ronchi CL; O'Reilly MW; Schreiner J; Asia M; Riester A; Perotti P; Libé R; Quinkler M; Canu L; Paiva I; Bugalho MJ; Kastelan D; Dennedy MC; Sherlock M; Ambroziak U; Vassiliadi D; Bertherat J; Beuschlein F; Fassnacht M; Deeks JJ; Biehl M; Arlt W
J Clin Endocrinol Metab; 2020 Mar; 105(3):e307-18. PubMed ID: 31665449
[TBL] [Abstract][Full Text] [Related]
14. Albumin/Mitotane Interaction Affects Drug Activity in Adrenocortical Carcinoma Cells: Smoke and Mirrors on Mitotane Effect with Possible Implications for Patients' Management.
Schiavon A; Saba L; Catucci G; Petiti J; Puglisi S; Borin C; Reimondo G; Gilardi G; Giachino C; Terzolo M; Lo Iacono M
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069023
[TBL] [Abstract][Full Text] [Related]
15. Outcome of adrenocortical carcinoma patients included in early phase clinical trials: Results from the French network ENDOCAN-COMETE.
Hescot S; Debien V; Hadoux J; Drui D; Haissaguerre M; de la Fouchardiere C; Vezzosi D; Do Cao C; Libé R; Le Tourneau C; Baudin E; Massard C; du Rusquec P;
Eur J Cancer; 2023 Aug; 189():112917. PubMed ID: 37277263
[TBL] [Abstract][Full Text] [Related]
16. Update on Biology and Genomics of Adrenocortical Carcinomas: Rationale for Emerging Therapies.
Lerario AM; Mohan DR; Hammer GD
Endocr Rev; 2022 Nov; 43(6):1051-1073. PubMed ID: 35551369
[TBL] [Abstract][Full Text] [Related]
17. Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma.
Puglisi S; Calabrese A; Basile V; Ceccato F; Scaroni C; Altieri B; Della Casa S; Loli P; Pivonello R; De Martino MC; Canu L; Russo M; Badalamenti G; Torlontano M; Stigliano A; Ferraù F; Arnaldi G; Saba L; Quirino A; Perotti P; Berchialla P; Terzolo M
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245135
[TBL] [Abstract][Full Text] [Related]
18. Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane.
Cantini G; Niccolai E; Canu L; Di Gloria L; Baldi S; Propato AP; Fei L; Nannini G; Puglisi S; Nesi G; Ramazzotti M; Amedei A; Luconi M
Endocr Relat Cancer; 2023 Oct; 30(10):. PubMed ID: 37695690
[TBL] [Abstract][Full Text] [Related]
19. The impact of mitotane therapy on serum-free proteins in patients with adrenocortical carcinoma.
Lech M; Ranasinghe R; Vincent RP; Taylor DR; Ghataore L; Luxton J; Lajeunesse-Trempe F; Roser P; Drakou EE; Chuah LL; Grossman AB; Aylwin SJB; Dimitriadis GK
Endocr Connect; 2024 Mar; 13(3):. PubMed ID: 38236710
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adjuvant radiation therapy in localized adrenocortical carcinoma.
Wu L; Chen J; Su T; Jiang L; Han Y; Zhang C; Zhou W; Jiang Y; Zhong X; Wang W
Front Endocrinol (Lausanne); 2023; 14():1308231. PubMed ID: 38260140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
